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Abstract
Background: Lenvatinib (LEN) has shown great efficacy but 
important toxicity in patients with advanced radioactive io-
dine-refractory (RAI-R) thyroid cancer (TC); a focused evalu-
ation of its impact on patients’ quality of life (QoL) is still lack-
ing. Our prospective study investigated the impact of this 
drug on QoL in a group of RAI-R TC patients treated at our 
centre. Methods: All patients filled in two questionnaires be-
fore and during treatment: (1) the Patient-Reported Out-
comes version of the Common Terminology Criteria for Ad-
verse Events adapted questionnaire, assessing prevalence, 
severity, and/or interference on daily activities of the most 
frequent symptomatic adverse events (AEs) reported in pre-
vious clinical trials during therapy with LEN, and (2) the Eu-
ropean Quality of Life 5 Dimensions 3 Levels (EQ-5D-3L) 
questionnaire, providing the EQ-5D index and the EQ visual 
analogue scale (EQ-VAS). Data from baseline questionnaires 
were compared with those obtained 3, 6, and 12 months af-
ter the start of treatment. Results: In our population (n = 20), 
an overall increased perception of symptomatic AEs emerged 
during treatment (statistically significant for abdominal 
pain, asthenia/fatigue, decreased appetite, and xerostomia). 
The median EQ-5D index and EQ-VAS scores after 3 months 
of treatment were lower than at baseline, almost returning 
to initial values after 12 months. Conclusion: RAI-R TC pa-
tients reported a general increase in prevalence and interfer-
ence on daily activities of symptomatic AEs during therapy 
with LEN. Self-perceived QoL initially decreased during ther-
apy. However, our data suggest that QoL could be restored 
after 12 months; this trend might partly reflect the impact of 
therapy optimisation. © 2020 European Thyroid Association
Published by S. Karger AG, Basel
Introduction
Treatment with lenvatinib (LEN), a multitarget tyro-
sine kinase inhibitor (TKI), has shown great efficacy in 
patients with advanced radioactive iodine-refractory 
(RAI-R) thyroid cancer (TC), both in clinical trials and 
in a real-life setting [1–4]. Nevertheless, frequent onset 
of adverse events (AEs) may decrease patients’ compli-
ance and, in some cases, lead to discontinuation of ther-
apy [5].
In recent years, growing interest has been dedicated to 
the study of the quality of life (QoL) perceived by the pa-
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uation of traditional endpoints such as efficacy and safety, 
the assessment of self-perceived mental and physical 
well-being has been introduced in many clinical trials [6]. 
Various instruments assessing health-related QoL, such 
as the European Quality of Life 5 Dimensions (EQ-5D) 
Questionnaire or the Functional Assessment of Cancer 
Therapy – General, have been employed to investigate the 
impact of anticancer therapies [7, 8].
Clinicians generally assess the toxicity of chemothera-
peutics using the standardised Common Terminology 
Criteria for Adverse Events (CTCAE) [9]. However, tox-
icity occurring between subsequent outpatient visits 
might not be adequately assessed. The Patient-Reported 
Outcomes version of the CTCAE (PRO-CTCAE) was 
conceived with the aim of capturing symptomatic toxici-
ties directly by the patient in order to minimise biases 
[10]. Ideally, it should allow detecting AEs at an earlier 
stage, thus simplifying their management. Moreover, it 
might improve communication between the patient and 
the physician, strengthening their therapeutic alliance.
The impact of treatment with TKIs on patients’ QoL 
has been extensively investigated both in haematological 
malignancies and in solid tumours [11, 12].
Among patients with locally advanced and/or meta-
static RAI-R TC, QoL was assessed during the multicen-
tre, double-blind, randomised, placebo-controlled phase 
III study evaluating the efficacy and safety of sorafenib 
(DECISION trial). A small but statistically significant 
worsening of QoL was observed in the treated patients 
compared to the placebo group [13]. Conversely, data 
concerning QoL were not collected in the international 
phase III study of LEN in advanced RAI-R TC (SELECT 
trial). A structured assessment of mental and physical 
well-being during treatment with this TKI in a real-life 
setting has not yet been reported to our knowledge. 
Therefore, the aim of our study was to prospectively ana-
lyse the impact of LEN on patients’ perceived QoL in a 
group of subjects with advanced RAI-R TC treated at our 
centre.
Materials and Methods
We enrolled all the patients with advanced RAI-R papillary, 
follicular, or poorly differentiated TC who started LEN at our cen-
tre between July 31, 2017 and January 31, 2019. Advanced RAI-R 
TC was defined as locally advanced and/or metastatic disease with 
no further indication for RAI therapy because of (1) disease pro-
gression during therapy with 131I, (2) lack of RAI uptake (partial 
or complete, assessed by 131I whole-body scan), or (3) cumulative 
RAI activity > 600 mCi according to the American Thyroid Asso-
ciation guidelines [14]. We included in this group also patients 
with advanced disease and an absolute contraindication to 131I 
therapy after L-thyroxine withdrawal or recombinant human thy-
rotropin stimulation. Previous treatment with other TKIs was not 
an exclusion criterion.
All patients had had radiologically confirmed progressive dis-
ease in the previous 12 months according to Response Evaluation 
Criteria in Solid Tumours (RECIST) 1.1 [15]. The drug was started 
at a daily dose of 24 mg, or at a lower dose by clinical judgement 
(e.g., age, risk of bleeding, or presence of severe comorbidities). 
AEs during LEN therapy were classified according to the CTCAE, 
version 4.03 [9]. In case of treatment-related high-grade toxicity, 
LEN was temporarily interrupted or dose tapered according to the 
summary of product characteristics of LEN [16]. Significant dis-
ease progression or serious toxicity (grade ≥3 according to the 
CTCAE, not otherwise manageable by symptomatic therapy, dose 
tapering or brief interruption of LEN) led to a permanent discon-
tinuation of LEN.
At baseline and at the follow-up visits, patients were asked to 
fill in two different questionnaires in the official Italian version 
(PRO-CTCAE adapted questionnaire and European Quality of 
Life 5 Dimensions 3 Levels [EQ-5D-3L] questionnaire) [7, 10]. The 
PRO-CTCAE adapted questionnaire investigated the 18 symp-
tomatic AEs experienced by at least 10% of treated patients in the 
SELECT trial. For every item, patients could choose an answer to 
define the presence, the frequency, the severity, and/or the inter-
ference with daily activities of a symptomatic AE during treatment 
[10]. The EQ-5D-3L questionnaire assesses QoL through the EQ-
5D descriptive system and the EQ visual analogue scale (EQ-VAS); 
a score (EQ-5D index) can be calculated combining these data into 
a dedicated algorithm [7].
Patients were asked to fill in the questionnaires anonymously 
before the consultation with the clinician in the waiting room and 
to give them back in a closed envelope.
The baseline characteristics of the patients included in the 
study are summarised using median and interquartile range, mean 
and standard deviation or numbers and percentages.
To assess treatment efficacy in our population, the disease con-
trol rate at the first on-therapy radiological assessment was calcu-
lated according to the RECIST criteria; progression-free and over-
all survival were estimated by the Kaplan-Meier method. The pro-
portions of patients with AEs (all grades) according to clinician’s 
assessment were defined and compared at baseline and at 3, 6, and 
12 months after the start of treatment by using Fisher’s exact test. 
The same analysis was performed for the percentage of patients 
who perceived the symptomatic AEs included in the PRO-CTCAE 
questionnaire before and during therapy. Furthermore, median 
values of EQ-5D index and EQ-VAS score at baseline were com-
pared with those at 3, 6, and 12 months after the start of therapy 
by using the Kruskal-Wallis test. A p value < 0.05 was considered 
significant. Statistical analyses were performed with the Stata 15.1 
software (StataCorp LP, College Station, TX, USA).
Results
Twenty consecutive RAI-R TC patients were enrolled 
in the study. Median age at cancer diagnosis was 58.7 
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ment with LEN was started after a median time of 6.8 
years (1.7–12.4 years) from the diagnosis of TC. The pa-
tients’ main clinical characteristics at baseline are sum-
marised in Table 1.
Six patients started treatment with LEN at a daily dose 
of 24 mg; a lower initial dose was chosen for the remain-
ing population, as displayed in Table 1. Median follow-up 
was 12.1 months (6.5–19.8 months). The first radiological 
evaluation was performed after a median time of 3.5 
months (2.8–4.2 months) from the start of the treatment; 
disease control rate was 80% (7 partial responses and 9 
stable diseases). During treatment, progression-free sur-
vival at 6 and 12 months was 80.0% (95% CI 55.1–91.9%) 
and 57.3% (95% CI 29.3–77.7%), while overall survival at 
6 and 12 months was 94.7% (95% CI 68.1–99.2%) and 
81.1% (95% CI 51.4–93.6%), respectively.
At least one AE was detected by clinicians in all pa-
tients during treatment; AEs of grade ≥3 were registered 
at least once in 80% of cases. The proportions of patients 
with AEs explored in the PRO-CTCAE questionnaire 
according to medical assessment are displayed in online 
supplementary Table 1 (for all online suppl. material, 
see www.karger.com/doi/10.1159/000508186). Further-
more, clinicians detected several AEs of grade ≥3 which 
were not included in the questionnaires: acute chole-
cystitis (n = 5), gallbladder stones (n = 2), congestive 
heart failure (n = 1), aortic dissection (n = 1), sepsis 
(n = 1), pneumonitis (n = 1), and pulmonary embolism 
(n = 1).
In order to manage toxicity during treatment, the LEN 
dose was reduced or temporarily interrupted in 80 and 
85% of patients, respectively, resulting in a mean dose of 
13.9 mg (± 5.5 mg) per day. The first dose reduction was 
necessary after a median time of 2.7 months (1.6–4.3 
months), while the first drug interruption occurred after 
a median time of 2.8 months (1.9–3.7 months). Treat-
ment with LEN was permanently discontinued in 2 sub-
jects for clinically significant progressive disease and in 2 
cases for severe toxicity (in 1 patient for asthenia, gastro-
intestinal symptoms, and recurrent pneumonitis, and in 
the other one for severe congestive heart failure).
A general increase in the perception of the AEs includ-
ed in the PRO-CTCAE questionnaires was initially reg-
istered during treatment when compared to baseline, 
reaching statistical significance in case of abdominal pain 
(severity, p = 0.02; interference, p < 0.01), decreased ap-
petite (severity, p = 0.04), xerostomia (severity, p = 0.02), 
and asthenia/fatigue (interference, p < 0.01) (Fig. 1). On-
line supplementary Table 2 shows the percentage of pa-
tients perceiving the AEs included in the PRO-CTCAE 
questionnaires before and during therapy.
The 12-month assessment was available for half of the 
initial population: within the first year of treatment, 2 pa-
tients died and 3 patients permanently discontinued the 
drug (in 2 cases for progressive disease and in 1 case for 
severe toxicity); moreover, in 5 patients the follow-up was 
> 6 months but < 12 months. The proportion of patients 
reporting symptomatic AEs after 12 months of treatment 



































Locoregional disease 17 85







































External beam radiotherapy 8 40
Previous treatment with sorafenib 3 15













































   
   
   
   
   
   
   
   























Eur Thyroid J 2021;10:65–7168
DOI: 10.1159/000508186
was generally lower than the one reported after 3 months 
of therapy.
In comparison to baseline, a decreased EQ-5D index 
was registered in all but 1 case during treatment, while a 
lower EQ-VAS was observed in 17 out of 20 patients. 
Among the 10 patients who filled in the 12-month ques-
tionnaire, the EQ-5D index and the EQ-VAS score were 
equal or higher than at baseline in 7 and 8 cases, respec-
tively.
The median EQ-5D index before the start of treatment 
was higher than after 3 and 6 months of therapy, but sim-
ilar to that observed after 12 months of treatment (p = 
0.04); an analogous trend was detected for the median 


























































































Fig. 1. Percentage of patients perceiving any degree of severity (at least mild) and interference on daily activities 
of AEs at baseline and during treatment with LEN (according to the PRO-CTCAE questionnaires. a Abdominal 
pain (severity). b Abdominal pain (interference). c Decreased appetite (severity). d Asthenia/fatigue (interfer-
ence). e Xerostomia (severity). AEs, adverse events; LEN, lenvatinib; PRO-CTCAE, Patient-Reported Outcomes 
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Discussion
In our population, a general increase in prevalence and 
interference of symptomatic AEs on daily activities was 
reported during therapy with LEN. Self-perceived QoL 
initially decreased during therapy, but it could ameliorate 
after 12 months of therapy.
LEN is considered a first-line systemic treatment for 
patients with RAI-R TC and progressive disease accord-
ing to the most recent guidelines [17]. Neither the phase 
III SELECT trial nor the main multicentre retrospective 
observational studies included the evaluation of patients’ 
perceived QoL.
In our population, only 3 patients had already been 
treated with another TKI (sorafenib in all cases) before 
starting therapy with LEN; therefore, the results of our 
analysis mostly reflect the real impact of LEN treatment 
rather than the cumulative effect of different TKIs.
The percentage of patients with impaired clinical con-
dition at baseline exceeded the proportion reported both 
in the SELECT trial and in the most relevant real-life 
studies; it implies the need of a personalised strategy from 
the very early phases of therapy.
Disease control rate at first radiological evaluation as 
well as progression-free and overall survival at 6 months 
of therapy confirm the clinical efficacy of LEN in terms of 
disease control, similar to other real-life studies, also in 
our population of patients with generally more advanced 
disease [2, 3].
At least one AE was recorded in all subjects, and severe 
AEs were registered in more than two-thirds of our pa-
tients. A statistically significant worsening of asthenia, 
diarrhoea, hand-foot syndrome, and xerostomia during 
treatment was detected at our evaluations when com-
pared to baseline. These findings confirm the consistent 
toxic profile of this drug already reported in similar stud-
ies. Interestingly, constitutional symptoms (e.g., asthenia, 
arthralgia, myalgia) were detected in more than one-third 
of the population at baseline, reflecting the presence of 
impaired clinical conditions even before the onset of ther-
apy.
During treatment, our patients felt an increased fre-
quency, severity, and interference on daily activities of the 
symptomatic AEs included in the PRO-CTCAE ques-
tionnaires, especially in the first months of therapy, inde-
pendently from the initial dose. These changes reached 
statistical significance in case of abdominal pain (severity 
and interference), decreased appetite (severity), xerosto-
mia (severity), and asthenia/fatigue (interference). The 
proportion of patients experiencing AEs at 12 months did 
not further increase.
The temporal trend of AE occurrence is similar to that 
recently described for weight loss during LEN therapy 
[18]. Taking into account that most patients underwent 
reduction and/or transient interruption of the drug with-
in the first 6 months, it could be speculated that the posi-
tive trend in the perception of AEs during therapy might 
partly reflect the impact of therapy optimisation in the 
management of drug toxicity. However, no solid conclu-
sion can be drawn from these limited data, especially con-
sidering that a filled-in 12-month questionnaire was 
available only for half of the population.
It could also be hypothesised that the initial tumour 
response to LEN therapy might have played a role in the 
self-perception of QoL, especially in patients with symp-

































Fig. 2. Median EQ-5D index and EQ-VAS before the start of ther-
apy and during treatment with LEN. EQ-5D, European Quality of 
Life 5 Dimensions; EQ-VAS, European Quality of Life visual ana-
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both the initial LEN dose and the Eastern Cooperative 
Oncology Group (ECOG) status could have influenced 
patients’ QoL. In our cohort, we were not able to find a 
significant association between these factors and QoL 
changes, due to the small sample and the presence of sev-
eral confounding factors in a real-life setting (i.e., choice 
of lower LEN starting dose in patients with poor baseline 
ECOG status and vice versa).
Both the median EQ-5D index and the EQ-VAS score 
before the start of treatment were significantly higher than 
the values registered after 3 and 6 months of therapy. 
These data reflect an initial reduction in self-perceived 
QoL after the start of therapy, which needs to be recog-
nised and properly managed in order to maintain and en-
force patients’ adherence to treatment. However, these 
QoL parameters became similar to the basal ones after 12 
months of treatment. In our population, patient-tailored 
modulation of treatment – together with the start of symp-
tomatic therapy – might have played a role in the improve-
ment of patients’ well-being during therapy, although spe-
cific data supporting this hypothesis are lacking.
It could be argued that our analysis might be biased by 
the fact that only patients who tolerated the drug could 
continue treatment and fill in all questionnaires. How-
ever, in our population only 2 patient discontinued ther-
apy with LEN for unmanageable toxicity: one between 6 
and 12 months of therapy and the other one after 24 
months of therapy.
The small sample size and the limited follow-up rep-
resent the main limitations of this pilot analysis of QoL, 
which needs to be explored in studies with larger cohorts 
of patients and with a prolonged duration. Also, the lack 
of a control group (patients with advanced RAI-R differ-
entiated TC not treated with LEN) represents a drawback 
of this analysis. Nevertheless, the prospective design of 
the study limited the potential biases of our research. 
Moreover, RAI-R differentiated TC is a relatively rare 
condition and LEN has been approved for the manage-
ment of this disease only for a few years.
The main strength of this study is that, for the first time, 
we prospectively gathered data focusing on self-perceived 
QoL in a group of RAI-R TC patients treated with LEN 
homogeneously managed at a single referral centre. Our 
findings draw attention to the patients’ perspective and 
help clinicians to gain increasing awareness in the real im-
pact of the drug on physical and mental well-being of these 
subjects. Patients should be informed about the possibil-
ity of perceiving several symptomatic AEs from the very 
early phases of treatment. The introduction of self-admin-
istered questionnaires for the evaluation of drug toxicity 
in a real-life setting might be helpful for clinicians, since 
it records mild symptoms that could not emerge during 
the outpatient visit. The early detection of AEs might im-
prove patients’ clinical outcome and preserve compliance 
and adherence to this lifelong treatment.
In conclusion, our study showed that a relevant toxic-
ity was recorded by clinicians during treatment with LEN 
for RAI-R TC. Patients reported a general increase in fre-
quency, severity, and interference on daily activities of 
symptomatic AEs on therapy when compared to baseline. 
Self-perceived QoL decreased during the first months of 
therapy; nevertheless, patients’ well-being seemed not to 
be worsened by the cumulative toxicity of the drug over 
time and QoL was restored after 12 months of therapy, 
perhaps reflecting, at least in part, the consequence of the 
proper management of the drug-related AEs. We believe 
that the early detection of self-perceived AEs as well as 
changes in QoL might improve patients’ clinical outcome 
and preserve compliance to this lifelong treatment. Fur-
ther investigations are needed to better understand the 
real global impact of LEN treatment on TC patients, es-
pecially in the long term.
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